{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:04:37Z","timestamp":1777860277015,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JRS"],"published-print":{"date-parts":[[2021,8,13]]},"abstract":"<jats:p>BACKGROUND: In antidepressant trials for pediatric patients with depression or anxiety disorders, the risk of suicidal events and other severe psychiatric adverse events such as aggression and agitation is increased with antidepressants relative to placebo. OBJECTIVE: To examine whether largely mentally healthy adolescents treated for a non-psychiatric condition are also at increased risk of suicidality and other severe psychiatric disorders. METHODS: This is a re-analysis of a placebo-controlled duloxetine trial for juvenile fibromyalgia based on the main journal article and additional data published in the online supplementary material and on ClinicalTrials.gov. Both serious adverse events related to psychiatric disorders and adverse events leading to treatment discontinuation were defined as severe treatment-emergent psychiatric adverse events. RESULTS: We found that a significant portion of adolescents had treatment-emergent suicidal ideation and behaviour as well as other severe psychiatric adverse events with duloxetine, but no such events were recorded on placebo. The incidence of severe treatment-emergent psychiatric adverse events was statistically significantly higher with duloxetine as compared to placebo. CONCLUSIONS: Antidepressants may put adolescents at risk of suicidality and other severe psychiatric disorders even when the treatment indication is not depression or anxiety.<\/jats:p>","DOI":"10.3233\/jrs-200033","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T12:39:26Z","timestamp":1604061566000},"page":"209-218","source":"Crossref","is-referenced-by-count":4,"title":["Suicidality and other severe psychiatric events with duloxetine: Re-analysis of safety data from a placebo-controlled trial for juvenile fibromyalgia"],"prefix":"10.1177","volume":"32","author":[{"given":"Michael P.","family":"Hengartner","sequence":"first","affiliation":[{"name":", Zurich University of Applied Sciences, Switzerland"},{"name":", University of Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pl\u00f6derl","sequence":"additional","affiliation":[{"name":", , Paracelsus Medical University Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"3","key":"10.3233\/JRS-200033_ref1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archpsyc.63.3.332","article-title":"Suicidality in pediatric patients treated with antidepressant drugs","volume":"63","author":"Hammad","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"1-2","key":"10.3233\/JRS-200033_ref2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/cap.2006.16.25","article-title":"Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: A meta-analysis","volume":"16","author":"Mosholder","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.3233\/JRS-200033_ref3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1192\/bjp.bp.105.011833","article-title":"Suicidal behaviour in youths with depression treated with new-generation antidepressants: Meta-analysis","volume":"189","author":"Dubicka","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.3233\/JRS-200033_ref4","first-page":"CD004851","article-title":"Newer generation antidepressants for depressive disorders in children and adolescents","volume":"11","author":"Hetrick","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JRS-200033_ref5","doi-asserted-by":"crossref","first-page":"i65","DOI":"10.1136\/bmj.i65","article-title":"Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports","volume":"352","author":"Sharma","year":"2016","journal-title":"BMJ"},{"issue":"9418","key":"10.3233\/JRS-200033_ref6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(04)16043-1","article-title":"Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data","volume":"363","author":"Whittington","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.3233\/JRS-200033_ref7","first-page":"240","article-title":"Outside the black box: Re-assessing pediatric antidepressant prescription","volume":"22","author":"Sparks","year":"2013","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"10.3233\/JRS-200033_ref8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fpsyt.2020.00018","article-title":"Duty to warn: Antidepressant black box suicidality warning is empirically justified","volume":"11","author":"Spielmans","year":"2020","journal-title":"Front Psychiatry"},{"issue":"18","key":"10.3233\/JRS-200033_ref9","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1056\/NEJMp1411138","article-title":"The FDA warning on antidepressants and suicidality\u2013why the controversy?","volume":"371","author":"Stone","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JRS-200033_ref10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fpsyt.2020.00478","article-title":"Antidepressant prescribing and suicide\/self-harm by Young Australians: Regulatory warnings, contradictory advice, and long-term trends","volume":"11","author":"Whitely","year":"2020","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.3233\/JRS-200033_ref11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/JRS-150645","article-title":"Suicidal risk from TADS study was higher than it first appeared","volume":"27","author":"Hogberg","year":"2015","journal-title":"Int J Risk Saf Med"},{"key":"10.3233\/JRS-200033_ref12","doi-asserted-by":"crossref","first-page":"h4320","DOI":"10.1136\/bmj.h4320","article-title":"Restoring Study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence","volume":"351","author":"Le Noury","year":"2015","journal-title":"BMJ"},{"key":"10.3233\/JRS-200033_ref13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JRS-2008-0426","article-title":"Clinical trials and drug promotion: Selective reporting of study 329","volume":"20","author":"Jureidini","year":"2008","journal-title":"Int J Risk Saf Med"},{"issue":"7444","key":"10.3233\/JRS-200033_ref14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/bmj.328.7444.879","article-title":"Efficacy and safety of antidepressants for children and adolescents","volume":"328","author":"Jureidini","year":"2004","journal-title":"BMJ"},{"issue":"11","key":"10.3233\/JRS-200033_ref15","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.euroneuro.2016.09.370","article-title":"Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis","volume":"26","author":"de Vries","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"10.3233\/JRS-200033_ref16","doi-asserted-by":"crossref","first-page":"e005535","DOI":"10.1136\/bmjopen-2014-005535","article-title":"Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: A cross-sectional study","volume":"4","author":"Hughes","year":"2014","journal-title":"BMJ Open"},{"issue":"19","key":"10.3233\/JRS-200033_ref17","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.3233\/JRS-200033_ref18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12916-015-0430-4","article-title":"Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles","volume":"13","author":"Tang","year":"2015","journal-title":"BMC Med"},{"issue":"9","key":"10.3233\/JRS-200033_ref19","doi-asserted-by":"crossref","first-page":"e1002127","DOI":"10.1371\/journal.pmed.1002127","article-title":"Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review","volume":"13","author":"Golder","year":"2016","journal-title":"PLoS Med"},{"issue":"6","key":"10.3233\/JRS-200033_ref20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jclinepi.2008.08.005","article-title":"Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials","volume":"62","author":"Tsang","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.3233\/JRS-200033_ref21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1192\/apt.12.5.320","article-title":"The antidepressant tale: Figures signifying nothing?","volume":"12","author":"Healy","year":"2006","journal-title":"Adv Psychiatr Treat"},{"issue":"7748","key":"10.3233\/JRS-200033_ref22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","article-title":"Scientists rise up against statistical significance","volume":"567","author":"Amrhein","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.3233\/JRS-200033_ref23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/0003-4819-144-4-200602210-00024","article-title":"Reporting of drug tolerance in randomized clinical trials: When data conflict with authors\u2019 conclusions","volume":"144","author":"Jonville-Bera","year":"2006","journal-title":"Ann Intern Med"},{"issue":"7003","key":"10.3233\/JRS-200033_ref24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.311.7003.485","article-title":"Absence of evidence is not evidence of absence","volume":"311","author":"Altman","year":"1995","journal-title":"BMJ"},{"key":"10.3233\/JRS-200033_ref25","doi-asserted-by":"crossref","unstructured":"Young PJ, Nickson CP, Perner A. When should clinicians act on non-statistically significant results from clinical trials? JAMA. 2020).","DOI":"10.1001\/jama.2020.3508"},{"issue":"1","key":"10.3233\/JRS-200033_ref26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12969-019-0325-6","article-title":"Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: Results from a randomized controlled trial","volume":"17","author":"Upadhyaya","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"10.3233\/JRS-200033_ref27","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.3233\/JRS-200033_ref28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/sim.3531","article-title":"Recommended tests for association in 2 \u00d7 2 tables","volume":"28","author":"Lydersen","year":"2009","journal-title":"Stat Med"},{"issue":"2","key":"10.3233\/JRS-200033_ref29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA\u2019s statement on p-values: Context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"issue":"9-10","key":"10.3233\/JRS-200033_ref30","first-page":"32","article-title":"Comparative validation of the S-STS, the ISST-Plus, and the C-SSRS for assessing the suicidal thinking and behavior FDA 2012 suicidality categories","volume":"11","author":"Sheehan","year":"2014","journal-title":"Innov Clin Neurosci"},{"issue":"9-10","key":"10.3233\/JRS-200033_ref31","first-page":"66","article-title":"The Columbia-Suicide severity rating scale (C-SSRS): Has the \u201cgold standard\u201d become a liability?","volume":"11","author":"Giddens","year":"2014","journal-title":"Innov Clin Neurosci"},{"issue":"12","key":"10.3233\/JRS-200033_ref32","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.4088\/JCP.14m09353","article-title":"Direct comparison of the psychometric properties of multiple interview and patient-rated assessments of suicidal ideation and behavior in an adult psychiatric inpatient sample","volume":"76","author":"Youngstrom","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.3233\/JRS-200033_ref33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1037\/ser0000210","article-title":"Predicting suicidal ideation in adolescents with chronic amplified pain: The roles of depression and pain duration","volume":"15","author":"Lewcun","year":"2018","journal-title":"Psychol Serv"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JRS-200033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:20Z","timestamp":1777509920000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JRS-200033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":33,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jrs-200033","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}